351 results on '"Merola J"'
Search Results
2. POS0543 KINETICS OF MUCOCUTANEOUS AND MUSCULOSKELETAL RESPONSES TO DEUCRAVACITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IN THE PHASE 2 PAISLEY TRIAL
3. AB0982 DOMAINS FOR INCLUSION IN A NOVEL TREATMENT RESPONSE MEASURE FOR SYSTEMIC LUPUS ERYTHEMATOSUS (TRM-SLE): RESULTS OF A MODIFIED DELPHI STUDY
4. AB1668-PARE IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES THROUGH 6 MONTHS OF GUSELKUMAB TREATMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: REAL-WORLD DATA FROM THE COREVITAS PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS REGISTRY
5. Tofacitinib efficacy, patient‐reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: Pooled analysis of two Phase III studies.
6. Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA–a retrospective study of claims data from 2009 to 2020
7. 183 Litifilimab modulates Type I interferon biomarkers in patients with cutaneous lupus erythematosus: Result of the LILAC Part B Phase 2 study
8. The Prevalence Of Atherosclerosis Identified On Coronary Ct Angiography Among Patients With Psoriatic Disease And Impact On Statin Utilization
9. POS1541 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 1 STUDY
10. POS1526 TREATMENT EFFECTS OF IXEKIZUMAB AND ADALIMUMAB AT THE INDIVIDUAL DIGIT LEVEL WITH NAIL AND DISTAL INTERPHALANGEAL JOINT INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS
11. AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
12. POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR
13. AB1097 MALIGNANCIES WITH LONG-TERM USE OF IXEKIZUMAB IN ADULTS WITH PSORIASIS, PSORIATIC ARTHRITIS, OR AXIAL SPONDYLOARTHRITIS: A POST-HOC ANALYSIS OF DATA FROM 25 RANDOMIZED CLINICAL TRIALS
14. AB1100 ACHIEVEMENT OF INCREASINGLY STRINGENT CLINICAL DISEASE CONTROL CRITERIA WAS ASSOCIATED WITH GREATER IMPROVEMENTS IN PHYSICAL FUNCTION, PAIN AND FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM BE OPTIMAL, A PHASE 3 RANDOMISED, PLACEBO-CONTROLLED STUDY
15. POS1535 EARLY IMPROVEMENT IN 3VAS/4VAS PREDICTS REDUCED RATES OF RADIOGRAPHIC CHANGE IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT
16. AB1105 LONG-TERM SAFETY OF IXEKIZUMAB TREATMENT IN ADULT PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS, OR AXIAL SPONDYLOARTHRITIS: A POST-HOC ANALYSIS OF END-OF-STUDY PROGRAM DATA RELATING TO MAJOR ADVERSE CARDIOVASCULAR EVENTS
17. AB1108 EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
18. POS0228 MINIMAL IMPORTANT DIFFERENCE (MID), MINIMAL DETECTABLE CHANGE (MDC), AND DISEASE ACTIVITY THRESHOLDS FOR TWO NOVEL COMPOSITE INSTRUMENTS (3VAS, 4VAS) IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF THREE PHASE 3 STUDIES
19. AB0574 LEVEL OF AGREEMENT ON CORE SIGNS OF CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) SUBTYPES AMONG DERMATOLOGISTS AND RHEUMATOLOGISTS AND DEVELOPMENT OF A CONCEPTUAL MODEL FOR CLE
20. AB1089 BIMEKIZUMAB EFFICACY IN HIGH-IMPACT AREAS FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: POOLED RESULTS THROUGH TWO YEARS FROM THE BE SURE AND BE RADIANT PHASE 3 TRIALS
21. AB0609 DESIGN OF A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL TRIAL OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE DISCOID AND/OR SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
22. POS0882 SCREENING/REFERRAL STRATEGIES FOR THE EARLY RECOGNITION OF PSA AMONG PATIENTS WITH PSORIASIS: RESULTS OF A GRAPPA SURVEY
23. POS1550 IMPACT OF ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 (TYK2) INHIBITOR, DEUCRAVACITINIB, ON PSORIASIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 2 TRIAL
24. AB1104 STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
25. 612 Treg depletion syndrome: Skin inflammation unleashed by ADCC depleting biologics
26. Executive Retreat: proceedings of the GRAPPA Executive Retreat 2022
27. The Frequency, Prevalence, And Outcomes Of Incidentally Detected Coronary Artery Calcium Using Artificial Intelligence Analysis Among Patients With Immune Mediated Inflammatory Diseases.
28. 257 Understanding health disparities among patients with psoriasis: Results from National Psoriasis Foundation annual surveys 2019 – 2021
29. 293 Ixekizumab demonstrates comprehensive psoriasis clearance in patients with moderate-to-severe psoriasis with scalp, nail, and/or palmoplantar involvement: Uncover-1, -2 trials through 5 years
30. 290 Risankizumab (RZB) for active psoriatic arthritis (PsA): Integrated subgroup analysis from 2 double-blind, placebo-controlled, phase 3 studies (KEEPsAKE 1 and KEEPsAKE 2)
31. 298 Sleep improvement with dupilumab in adults with moderate-to-severe atopic dermatitis: Results of the DUPISTAD study
32. 222 Geographic distribution of primary discoid lupus erythematosus and environmental hazards in Massachusetts
33. LB988 VISIBLE: Guselkumab (GUS) skin and scalp clearance in skin of color (SOC) participants (pts) by baseline (BL) inflammatory disease burden
34. 155 Screening and disease activity assessment for psoriatic arthritis using the PEST and PsAID-12
35. 167 Combination therapy use in patients with psoriatic arthritis in a real-world dataset
36. 154 Assessing musculoskeletal symptom burden in a cohort of patients with hidradenitis suppurativa using the IDEOM MSK-Q
37. POS1039 DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS: ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND ITS COMPONENTS
38. POS1077 LARGE JOINT INVOLVEMENT AND SUBSTANTIAL DISEASE BURDEN IN PATIENTS WITH OLIGOARTICULAR AND POLYARTICULAR PSORIATIC ARTHRITIS IN THE MULTINATIONAL UPLIFT SURVEY
39. AB1473 EFFICACY RESPONSES ACROSS DISEASE SEVERITY AND TREATMENT HISTORY SUBGROUPS OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS TREATED WITH GUSELKUMAB: POOLED RESULTS FROM VOYAGE-1 AND VOYAGE-2 THROUGH 5 YEARS
40. POS1032 RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS: INTEGRATED SUBGROUP ANALYSIS FROM 2 DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDIES (KEEPsAKE 1 AND KEEPsAKE 2)
41. POS0072 CONSISTENT LONG-TERM GUSELKUMAB EFFICACY ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE PATIENT CHARACTERISTICS
42. AB0893 An Analysis of Fatigue in Patients With Psoriatic Disease Utilizing SF-36 Vitality Scores: Results Through Week 24 in Phase 3 Trials of Guselkumab in Patients With Psoriasis and Psoriatic Arthritis
43. POS1099 QUALITY OF LIFE, WORK IMPAIRMENT, AND DAILY ACTIVITY IMPAIRMENT OF PATIENTS WITH PSORIASIS VERSUS PSORIATIC ARTHRITIS: A REAL-WORLD SURVEY IN US AND EUROPE
44. POS1029 EFFECTS OF TREATMENT WITH RISANKIZUMAB ON MINIMAL DISEASE ACTIVITY (MDA) AND DISEASE ACTIVITY IN PSORIATIC ARTHRITIS (DAPSA): AN ANALYSIS OF THE KEEPsAKE-1 AND -2 TRIALS
45. OP0255 BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY
46. POS0081 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 1 STUDY
47. POS0309 ARE PATIENTS’ AND RHEUMATOLOGISTS’ PERCEPTIONS OF THE BURDEN AND TREATMENT OF PSORIATIC ARTHRITIS ALIGNED? RESULTS FROM THE UPLIFT SURVEY
48. LB0001 BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY
49. AB0887 Designing a Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Guselkumab Dosing Interval in Psoriatic Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibition
50. AB0924 Individual Digit Level Nail Involvement and Joint Assessment in Patients with Nail Psoriasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.